uploads/2017/12/Branded-Rx-prod-1.png

Behind Valeant’s Branded Drugs: Other 3Q17 Performances

By

Updated

Arestin and Solodyn revenue trends

In 3Q17, Valeant Pharmaceuticals’ (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter. Arestin reported revenues of $78 million for the first nine months of 2017.

In 3Q17, Solodyn generated revenues of $14 million, compared with $26 million in 3Q16. In 3Q17, Solodyn witnessed a 8% rise on a quarter-over-quarter basis.

Arestin (minocycline) is used for the treatment of bacterial infections such as respiratory infections, skin infections, urinary tract infections, and gonorrhea.

Solodyn is used for the treatment of moderate to severe acne in individuals aged above 12 years. Solodyn’s competition in the acne therapy market includes Pfizer’s (PFE) Vibramycin and the Medicines Company’s (MDCO) Minocin.

Article continues below advertisement

Jublia and Elidel revenue trends

In 3Q17, Jublia generated revenues of $19 million, compared with $39 million in 3Q16. In 3Q17, Jublia witnessed a 6% rise on a quarter-over-quarter basis.

Jublia (efinaconazole) is used for the treatment of onychomycosis of the toenails caused by trichophyton rubrum and trichophyton mentagrophytes.

In 3Q17, Elidel reported revenues of $21 million, which is ~19% lower on a YoY basis but 17% higher quarter-over-quarter. Elidel reported revenues of $60 million for the first nine months of 2017.

Elidel is used as a second-line treatment for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised individuals who didn’t adequately respond to other topical prescription drugs or for whom such therapy is not recommended.

In the marketplace, Elidel’s competition includes Pfizer’s (PFE) Eucrisa and Astellas Pharma’s (ALPMY) Prograf.

Relistor and Retin-A Franchise revenue trends

In 3Q17, Relistor reported revenues of $17 million, compared with $22 million in 3Q16. Relistor reported revenues of $46 million for the first nine months of 2017.

Relistor (methylnaltrexone bromide) is used for the treatment of opioid-induced constipation (or OIC) in adult individuals with chronic non-cancer pain.

In 3Q17, the Retin-A franchise generated revenues of $27 million, which was ~16% lower on a YoY basis but 13% higher quarter-over-quarter. Retin-A is a type of vitamin A.

Notably, the PowerShares Dynamic Pharmaceuticals Portfolio (PJP) invests ~3.49% of its total portfolio holdings in Valeant Pharmaceuticals.

Advertisement

More From Market Realist